FDA Approves New Myeloma Treatment as PBMs Embrace Price Comparisons
By Editor • August 14, 2026 • 1 min read
The FDA has granted approval for a groundbreaking oral treatment for advanced multiple myeloma by Bristol Myers Squibb, introducing a new class of medication for this blood cancer.
This drug is notable as it is the first to receive approval in the U.S. utilizing a more sensitive measure of remission. In related news, pharmacy benefit managers are now adopting TrumpRx price comparisons.
Source: www.statnews.com
#Bristol Myers Squibb #cancer treatment #FDA #multiple myeloma #TrumpRx
